Trial Profile
Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Doxorubicin
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Jan 2021 Planned End Date changed from 1 Jul 2020 to 1 Sep 2022.
- 26 Jan 2021 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2021.
- 26 Jan 2021 Status changed from recruiting to active, no longer recruiting.